Leadership & Pay ·
NanoViricides extends employment agreements for President Dr. Anil R. Diwan and CFO Meeta Vyas through June 2027
NNVCNanoviricides, Inc.
NanoViricides, Inc. announced the extension of employment agreements for President Dr. Anil R. Diwan and CFO Meeta Vyas, effective July 1, 2026, through June 30, 2027. Dr. Diwan’s agreement includes a $400,000 annual base salary and the grant of 10,204 shares of Series A Preferred Stock vesting quarterly until June 30, 2027. Ms. Vyas continues under her existing terms with an amendment allowing reimbursement for up to 50% of health insurance costs, capped at $2,500 per month. These arrangements secure key executive leadership and define their compensation structures for the upcoming fiscal year. The company operates in the biotechnology industry, focusing on the development of antiviral therapeutics.